You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for 7,8-Dihydroxyflavone
7,8-Dihydroxyflavone is a tyrosine kinase receptor B (TrkB) agonist that binds to the extracellular domain of the receptor (Kd = 320 nM). Inhibits glutamate-triggered apoptosis in hippocampal neurons in vitro and in vivo. Exhibits neuroprotective effects in an HD mouse model.
Technical Data for 7,8-Dihydroxyflavone
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for 7,8-Dihydroxyflavone
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for 7,8-Dihydroxyflavone
The following data is based on the product molecular weight 254.24. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.93 mL||19.67 mL||39.33 mL|
|5 mM||0.79 mL||3.93 mL||7.87 mL|
|10 mM||0.39 mL||1.97 mL||3.93 mL|
|50 mM||0.08 mL||0.39 mL||0.79 mL|
Product Datasheets for 7,8-Dihydroxyflavone
References for 7,8-Dihydroxyflavone
References are publications that support the biological activity of the product.
Jang et al (2010) A selective TrkB agonist with potent neurotrophic activities by 7,8-dihydroxyflavone. Proc.Natl.Acad.Sci.USA 107 268
Andero et al (2012) 7,8-dihydroxyflavone, a TrkB receptor agonist, blocks long-term spatial memory impairment caused by immobilzation stress in rats. Hippocampus 22 399 PMID: 21136519
Jiang et al (2013) Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease. Hum.Mol.Genet. 22 2462 PMID: 23446639
If you know of a relevant reference for 7,8-Dihydroxyflavone, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: 7,8-Dihydroxyflavone, 7,8-Dihydroxyflavone supplier, agonists, TrkB, Neurotrophin, Receptors, Tyrosine, Kinases, RTKs, 7,8-DHF, Trk, 3826, Tocris Bioscience
9 Citations for 7,8-Dihydroxyflavone
Citations are publications that use Tocris products. Selected citations for 7,8-Dihydroxyflavone include:
Mantilla and Ermilov (2012) The novel TrkB receptor agonist 7,8-dihydroxyflavone enhances neuromuscular transmission. PLoS One 45 274 PMID: 22246885
Meltser et al (2014) TrkB-mediated protection against circadian sensitivity to noise trauma in the murine cochlea. Curr Biol 24 658 PMID: 24583017
Al-Qudah et al (2014) Brain-derived neurotrophic factor enhances cholinergic contraction of longitudinal muscle of rabbit intestine via activation of phospholipase C. Am J Physiol Gastrointest Liver Physiol 306 G328 PMID: 24356881
Choi et al (2013) Effect of 7,8-dihydroxyflavone as an antioxidant on in vitro maturation of oocytes and development of parthenogenetic embryos in pigs. Muscle Nerve 59 450 PMID: 23748647
Greising et al (2017) Chronic TrkB agonist treatment in old age does not mitigate diaphragm neuromuscular dysfunction. Physiol Rep 5 PMID: 28082429
Chitranshi et al (2015) Exploring the Molecular Interactions of 7,8-Dihydroxyflavone and Its Derivatives with TrkB and VEGFR2 Proteins. Purinergic Signal 16 21087 PMID: 26404256
Abcejo et al (2012) Brain-derived neurotrophic factor enhances calcium regulatory mechanisms in human airway smooth muscle. Int J Mol Sci 7 e44343 PMID: 22952960
Shamblott et al (2016) Neurogenin 3 is regulated by neurotrophic tyrosine kinase receptor type 2 (TRKB) signaling in the adult human exocrine pancreas. Cell Communication and Signaling 14 23 PMID: 27659207
Chen et al (2014) BDNF released during neuropathic pain potentiates NMDA receptors in primary afferent terminals. Eur J Neurosci 39 1439 PMID: 24611998
Do you know of a great paper that uses 7,8-Dihydroxyflavone from Tocris? Please let us know.
Reviews for 7,8-Dihydroxyflavone
There are currently no reviews for this product. Be the first to review 7,8-Dihydroxyflavone and earn rewards!
Have you used 7,8-Dihydroxyflavone?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the MSN intracellular signaling pathways implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.